Form 8-K - Current report:
SEC Accession No. 0001104659-25-103254
Filing Date
2025-10-28
Accepted
2025-10-28 17:07:47
Documents
17
Period of Report
2025-10-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2529544d2_8k.htm   iXBRL 8-K 34742
2 EXHIBIT 4.1 tm2529544d2_ex4-1.htm EX-4.1 98592
3 EXHIBIT 5.1 tm2529544d2_ex5-1.htm EX-5.1 14409
4 EXHIBIT 10.1 tm2529544d2_ex10-1.htm EX-10.1 209344
5 EXHIBIT 10.2 tm2529544d2_ex10-2.htm EX-10.2 17670
9 GRAPHIC tm2528502d2_ex5-1img01.jpg GRAPHIC 4919
  Complete submission text file 0001104659-25-103254.txt   640161

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA anvs-20251026.xsd EX-101.SCH 3020
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20251026_lab.xml EX-101.LAB 34239
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20251026_pre.xml EX-101.PRE 22362
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2529544d2_8k_htm.xml XML 3790
Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 251425763
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)